Supporting the Hip Joint with ChondroFiller: Labrum-Related Wear and Early Arthritis
Hip pain in active adults often comes down to one of two overlapping problems: a worn or damaged labrum, and the early cartilage loss that tends to follow. If you are at the stage of weighing options — not yet needing joint replacement but not finding physiotherapy alone sufficient — the ChondroFiller injection is one non-surgical option worth understanding clearly. This article explains what it involves, what the evidence supports, and where the boundaries of that evidence currently lie.
Labrum Wear and Early Arthritis
The acetabular labrum is a fibrocartilage ring that seals the hip socket, contributes to joint stability, and helps distribute load across the femoral head. When it is torn or chronically worn — whether from femoroacetabular impingement, sport, or accumulated stress — the articular cartilage on the femoral head and acetabulum becomes more vulnerable. Reduced cushioning means higher contact stresses, and over time this can accelerate the early cartilage loss that characterises early osteoarthritis.
At this pre-advanced stage, the joint still has meaningful cartilage remaining, which is precisely when biological support options are most relevant. The aim is not to reverse established arthritis but to protect and support what remains.
What ChondroFiller Is
ChondroFiller is a Class III CE-marked type I collagen hydrogel scaffold, manufactured by Meidrix Biomedicals in Germany and available in the UK under specialist prescription. It is an acellular (cell-free) device: it contains no cells of its own. When delivered into a joint it self-gels within approximately three to five minutes, forming a porous three-dimensional matrix that provides physical support to worn cartilage surfaces and encourages the patient's own progenitor cells to migrate in and begin remodelling the matrix towards cartilage tissue over the following months.
The CE Class III designation and the published outcome and safety data belong to ChondroFiller as a device. It is the scaffold itself that carries this regulatory status.
The ChondroFiller Injection for the Hip
For the hip, ChondroFiller can be delivered as a non-surgical, ultrasound-guided outpatient injection. No theatre, no incision, and no general anaesthetic are required. The clinician uses ultrasound guidance to place the collagen gel accurately into the intra-articular space, where it may settle over worn cartilage surfaces to add a supportive, cushioning layer and help reduce the grinding sensation that often accompanies early cartilage loss.
This injection approach is best suited to accessible lesions and cases of early, localised wear — typically adults with labrum-related cartilage stress who do not yet have advanced-stage osteoarthritis. Because it is non-surgical, recovery involves sensible activity advice and physiotherapy where appropriate rather than a formal surgical rehabilitation programme.
When Surgery Becomes the Relevant Option
For larger or structurally more complex hip cartilage defects — or where the labrum tear itself requires direct arthroscopic attention — a non-surgical injection may not be sufficient on its own. In those situations, the Liquid Cartilage procedure may be the appropriate next step.
Liquid Cartilage is the name for Professor Paul Y. F. Lee's keyhole surgical protocol (the Lee Liquid Cartilage Protocol), which is a distinct procedure from the ChondroFiller injection. It is genuine surgery performed under anaesthetic in a theatre setting via hip arthroscopy. The protocol delivers the ChondroFiller scaffold arthroscopically alongside biological adjuncts — platelet-rich fibrin, platelet-rich plasma, and tranexamic acid — and, where indicated, the patient's own mesenchymal stem cells derived from bone-marrow aspirate concentrate or micro-fragmented fat. The combination is designed to create an optimal biological environment for cartilage regeneration within the joint. Recovery follows a structured rehabilitation programme rather than the simple post-injection recovery of the non-surgical route.
Understanding which pathway is appropriate — injection or keyhole surgery — is part of the initial specialist assessment. The two are not interchangeable names for the same thing.
What the Evidence Says
Most published clinical experience with ChondroFiller as a scaffold comes from the knee and ankle. Hip-specific, gold-standard randomised controlled trial data are not yet available, and the evidence base is still developing. Some studies of similar collagen-based intra-articular interventions in the hip have reported encouraging early results, and a 2023 study using the ChondroFiller scaffold for trapeziometacarpal (thumb-base) osteoarthritis reported improvements in pain and grip function (Corain M, Zanotti F, Giardini M et al. The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage, 2023). Because hip-specific evidence is limited, specialists discuss the injection cautiously and on an individual basis. Responses vary and benefits cannot be guaranteed.
Who May Be Suitable
The ChondroFiller injection may suit adults who have localised hip joint wear — often related to a labrum tear or early post-impingement cartilage damage — without advanced arthritis. The joint should retain reasonable structural integrity, and significant inflammatory arthritis or end-stage joint degeneration would generally point toward other management. Suitability is determined on an individual basis after imaging review and clinical assessment.
Conclusion
The ChondroFiller injection offers a non-surgical option for adults with labrum-related hip wear and early arthritis who are looking for biologically active support beyond physiotherapy. It is not a cure, and it is not equivalent to the surgical Liquid Cartilage procedure, which addresses more complex or structurally significant hip cartilage problems. At the London Cartilage Clinic, the team provides an individual assessment to determine whether the injection, the surgical protocol, or another management strategy is most appropriate for your hip. Always seek advice from a qualified healthcare professional before pursuing any treatment.
References
Corain M, Zanotti F, Giardini M, Gasperotti L, Invernizzi E, Biasi V, Lavagnolo U. The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage, 2023.
Frequently Asked Questions
- ChondroFiller is a CE-marked type I collagen scaffold. The ChondroFiller injection delivers this scaffold via an ultrasound-guided outpatient injection — no surgery involved. Liquid Cartilage is Professor Lee's keyhole surgical protocol, performed in theatre under anaesthetic, which places the same ChondroFiller scaffold arthroscopically alongside biological adjuncts such as platelet-rich fibrin and, where indicated, the patient's own mesenchymal stem cells. They are two different delivery pathways suited to different clinical situations.
- Adults with localised hip joint wear — often related to labrum damage or early post-impingement cartilage stress — who do not yet have advanced osteoarthritis. The joint should retain reasonable structural integrity. Suitability is assessed individually after imaging review and clinical examination; it is not appropriate for all hip conditions.
- The clinician uses ultrasound guidance to inject the collagen gel accurately into the hip joint as an outpatient procedure. The gel self-sets within a few minutes, forming a porous matrix over worn cartilage surfaces. The patient's own progenitor cells migrate into this scaffold over subsequent months, with the aim of providing a supportive, cushioning layer and reducing joint irritation. There is no incision and no general anaesthetic.
- Recovery after the non-surgical injection is generally straightforward. There is no surgical rehabilitation programme; instead, patients follow sensible activity guidance and physiotherapy where helpful. There is no formal period of protected weight-bearing of the kind required after the keyhole surgical procedure.
- No. Most published clinical data for ChondroFiller as a scaffold come from the knee and ankle. Hip-specific trial data are more limited and still emerging. Some encouraging early results exist for similar intra-articular collagen interventions in the hip, and a 2023 study reported positive outcomes at the thumb base. Specialists discuss the hip injection cautiously on an individual basis, and benefits cannot be guaranteed.
Where to go from here
A few next steps tailored to what you have just read.
Legal & Medical Disclaimer
This article is written by an independent contributor and reflects their own views and experience, not necessarily those of London Cartilage Clinic. It is provided for general information and education only and does not constitute medical advice, diagnosis, or treatment.
Always seek personalised advice from a qualified healthcare professional before making decisions about your health. London Cartilage Clinic accepts no responsibility for errors, omissions, third-party content, or any loss, damage, or injury arising from reliance on this material.
If you believe this article contains inaccurate or infringing content, please contact us at [email protected].
